Voyager Therapeutics, Inc. revenue

Voyager Therapeutics, Inc.'s revenue was $40.4m in fiscal 2025, down 49.5% on the year before. Since fiscal 2015 ($17.3m) it has grown at a compound 8.8% a year. Over the last twelve months it was $34.5m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Voyager Therapeutics, Inc.: revenue history, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	17	14	10	8	104	171	37	41	250	80	40	34
Growth on the year before	—	−18.0%	−28.7%	−24.8%	+>999%	+63.9%	−78.1%	+9.3%	+511.2%	−68.0%	−49.5%	—

US$ millions unless shown otherwise. Fiscal quarters.

Voyager Therapeutics, Inc.: revenue history, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	25	6	6	5	13	15	3	3
Growth on the same quarter a year before	—	—	—	—	−45.7%	+144.3%	−59.9%	−39.1%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Voyager Therapeutics, Inc.	$34.5m	-19.1%	-43.9%
Bioharvest Sciences Inc.	$34.5m	37.0%	—
C4 Therapeutics, Inc.	$35.0m	2.3%	29.8%
Foghorn Therapeutics Inc.	$36.7m	52.0%	19.1%
Nanobiotix S.a.	$36.9m	678.4%	—
Zymeworks Inc.	$37.1m	-69.8%	-56.4%

Compare with peers

Head to head: BHST vs VYGR CCCC vs VYGR FHTX vs VYGR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Voyager Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Voyager Therapeutics, Inc.